| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 0 | - |
| Operating Income | -65.4MM | -5% |
| Operating Expenses | 65.4MM | -5% |
| Net Income | -61.9MM | -6% |
| R&D | 46.8MM | -9% |
| G&A | 18.6MM | +7% |
| Interest Expense | 469K | +0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
In this article, we will take a look at Billionaire Lee Ainslie’s top 10 stock picks. For more Ainslie’s stocks, head on over to Billionaire Lee Ainslie’s Top 5 Stock Picks. Hedge fund managers are known for investing in various asset classes in the race to unlock value in the market. But not Lee Ainslie, a […]
Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.
The consensus price target hints at a 167.1% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CRANBURY, N.J., November 06, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial results for the quarter ending September 30, 2023, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.
Let me tell you why I and how I added this biotech name, and look at the bigger picture of the market and economy. Despite good news on a myriad of fronts, the stock was clearly swimming upstream as the biotech sector sold off hard over the past few months. This gene therapy developer garnered a priority review from the Food and Drug Administration early in October for its marketing application for potentially its first approved product, a candidate to treat Leukocyte Adhesion Deficiency-I, a ...
Rocket Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. The fund declined 6.05% (Institutional Shares) in the quarter compared to a 3.88% loss for the Russell 3000 Health Care Index and a 3.27% loss for the S&P 500 Index. […]
CRANBURY, N.J., October 19, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced presentations at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) in Brussels, Belgium, taking place October 24-27. Updated data will be presented from the Phase 1 clinical trial of RP-L301 for Pyruvate Kinase Deficiency
CRANBURY, N.J., October 02, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte